Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3525)
All Articles published online
|
Publishing Process of This Article
|
Oct 6, 2022 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. World J Clin Cases 2022; 10(28): 10085-10096 [PMID: 36246814 DOI: 10.12998/wjcc.v10.i28.10085] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i28/10085.htm |
| Number | Citing Articles |
| 1 |
Sheila F. Lumley, Marion Delphin, Jolynne F. Mokaya, Cedric C.S. Tan, Emily Martyn, Motswedi Anderson, Ka Chun Li, Elizabeth Waddilove, Gloria Sukali, Louise O. Downs, Khadija Said, Dorcas Okanda, Cori Campbell, Eli Harriss, Yusuke Shimakawa, Philippa C. Matthews. A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir. Journal of Clinical Virology 2024; 174: 105711 doi: 10.1016/j.jcv.2024.105711
|